Recent Updates from SKIPPirr – Strategies for Preventing IRR with IV Amivantamab in Patients with EGFR-mutated NSCLC
A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.
Video content above is prompted by the following:
- Please give an overview of monoclonal antibody infusion-related reactions (IRRs) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).
- Please give an overview of the updated results from the phase 2 SKIPPirr trial, focusing on prevention of IRRs. What are the key takeaways?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
